Experimental drug aims to wake up immune system against Hard-to-Treat leukemia
NCT ID NCT06626633
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This early-phase study tests a new drug called CRD3874-SI in 6 adults with acute myeloid leukemia that has returned or not responded to standard treatment. The drug activates a protein called STING, which helps the immune system recognize and kill cancer cells. The main goals are to check safety and find the best dose for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Maryland, Baltimore
Baltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.